Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.

PloS One
Yin LiangKeith Demarest

Abstract

Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). (14)C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing human, rat, or mouse SGLT2 or SGLT1; (3)H-2-deoxy-d-glucose uptake in L6 myoblasts; and 2-electrode voltage clamp recording of oocytes expressing human SGLT3 were analyzed. Graded glucose infusions were performed to determine rate of urinary glucose excretion (UGE) at different blood glucose (BG) concentrations and the renal threshold for glucose excretion (RT(G)) in vehicle or canagliflozin-treated Zucker diabetic fatty (ZDF) rats. This study aimed to characterize the pharmacodynamic effects of canagliflozin in vitro and in preclinical models of T2DM and obesity. Treatment with canagliflozin 1 mg/kg lowered RT(G) from 415±12 mg/dl to 94±10 mg/dl in ZDF rats while maintaining a threshold relationship between BG and UGE with virtually no UGE observed when BG was below RT(G). Canagliflozin dose-dependently decreased BG concentrations in db/db mice treated acutely. In ZDF rats treated for 4 weeks, canagliflozin decreased glycated hemoglobin (HbA1c) and improved measures of insulin secretion. In obese animal mo...Continue Reading

References

Oct 1, 1987·The Journal of Clinical Investigation·L RossettiR A DeFronzo
Jun 1, 1997·Journal of the American Society of Nephrology : JASN·M KamranJ H Dominguez
Nov 14, 1998·The American Journal of Physiology·E M Wright
Sep 11, 2001·The Journal of Clinical Endocrinology and Metabolism·S E Kahn
Dec 28, 2002·Diabetes·Alexandra E ButlerPeter C Butler
May 16, 2003·Pflügers Archiv : European journal of physiology·Ernest M Wright, Eric Turk
Sep 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ana Diez-SampedroHermann Koepsell
Feb 1, 1951·The Journal of Clinical Investigation·S J FARBERD P EARLE
Dec 30, 2004·Diabetes/metabolism Research and Reviews·Joel R L EhrenkranzJesse Roth
Apr 22, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Klaus RaveEwoud-Jan van Hoogdalem
Nov 18, 2006·Molecular Pharmacology·Andrew A VossErnest M Wright
Jan 16, 2007·Journal of Internal Medicine·E M WrightD F Loo
Oct 16, 2007·Diabetes Care·Thomas J HoergerJinan B Saaddine
Dec 1, 2007·Endocrine Reviews·Décio L EizirikMiriam Cnop
Feb 29, 2008·American Journal of Human Genetics·Barbara Kloeckener-GruissemWolfgang Berger
Dec 31, 2008·Diabetes Care·James F ListFred T Fiedorek
Apr 10, 2009·Kidney International·George L BakrisErnest M Wright
Nov 1, 2007·Journal of Diabetes Science and Technology·Lalo MagniClaudio Cobelli
Nov 7, 2009·The Journal of Clinical Endocrinology and Metabolism·Sunil Nair, John P H Wilding
Dec 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·René Santer, Joaquim Calado
Dec 17, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·S Del Prato
Mar 31, 2010·Nature Reviews. Nephrology·Amanda Mather, Carol Pollock
May 29, 2010·Nature Reviews. Drug Discovery·Edward C Chao, Robert R Henry
Jul 10, 2010·Journal of the American Society of Nephrology : JASN·Volker VallonTimo Rieg

❮ Previous
Next ❯

Citations

Oct 8, 2014·Chemico-biological Interactions·Sandra De JongheMark D Johnson
Aug 19, 2014·Chemico-biological Interactions·Rao N V S MamidiMark D Johnson
Jun 4, 2013·Drugs·Shelley Elkinson, Lesley J Scott
Aug 28, 2013·Expert Review of Clinical Pharmacology·Vasileios Andrianesis, John Doupis
Apr 18, 2013·Expert Opinion on Drug Metabolism & Toxicology·Elizabeth M LamosStephen N Davis
Mar 5, 2013·Expert Opinion on Investigational Drugs·William N Washburn, Simon M Poucher
Oct 24, 2015·Current Medical Research and Opinion·Vlado PerkovicGary Meininger
Sep 26, 2015·Diabetes, Obesity & Metabolism·Surya Panicker RajeevJohn P H Wilding
Jul 15, 2015·Proceedings of the National Academy of Sciences of the United States of America·Claudio ScafoglioErnest M Wright
Oct 20, 2012·Annales d'endocrinologie·Thomas CunyBertrand Cariou
Apr 1, 2014·Kidney International·Richard E Gilbert
Mar 8, 2013·Diabetes, Obesity & Metabolism·J-F YaleG Meininger
Nov 15, 2013·Obesity·Harold E BaysWilliam Canovatchel
Mar 27, 2015·Nephrology·Richard BrunnerUlrike Holzinger
Apr 20, 2016·Frontiers in Pharmacology·Husnia I Marrif, Salma I Al-Sunousi
Apr 22, 2015·Journal of Pharmacological Sciences·Takahiro OgumaMasaharu Shiotani

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

nlinfit
Matlab
Prism

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.